Call for breast cancer drug price reduction

April 23, 2014 1:15 pm

Campaigners are calling on pharmaceutical company Roche to cut the price of a pioneering new breast cancer treatment amid indications the NHS drugs watchdog is set to reject its use on the service on cost grounds. NICE said the £90,000 cost of trastuzumab emtansine is not justifiable. Sir Andrew Dillon, NICE Chief Executive, said: “We had hoped that Roche would have recognised the challenge the NHS faces in managing the adoption of expensive new treatments by reducing the cost of Kadcyla to the NHS.”

Yahoo News.

April 23, 2014 1:15 pm

*/?>

Sign up to receive analysis on policy developments across our specialist sectors








Contact us

For more information about how Whitehouse can help you, please contact:

Isabella Sharp
t: +44 (0)20 3855 5760
m: +44 (0)7813 307490
isabella.sharp@whitehouseconsulting.co.uk

Viviana Spaghetti
t: +44 (0)20 3855 5760
m: +44 (0)7583 051119
viviana.spaghetti@whitehouseconsulting.co.uk

For media enquiries, please contact:
Mayar Raouf

t: +44 (0)20 3855 5760
m: +44 (0)7502 327092
mayar.raouf@whitehouseconsulting.co.uk

For career and jobs information, please contact:
t: +44 (0)20 3855 5760
recruitment@whitehouseconsulting.co.uk

For general enquiries, please contact:
t: +44 (0)20 3855 5760
info@whitehouseconsulting.co.uk

Sign up for the latest news

  • * Denotes required fields
  • This field is for validation purposes and should be left unchanged.